Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate
(eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction …

Novel pharmacologic treatment options reduce mortality and morbidity in a cost‐effective
manner in patients with heart failure (HF). Undisputedly, the effective implementation of …

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

The advent of newly available medical therapies for heart failure with reduced ejection
fraction (HFrEF) has resulted in many potential therapeutic combinations, increasing …

Given the high risk of adverse outcomes in patients with heart failure and reduced ejection
fraction (HFrEF), there is an urgent need for the initiation and titration of guideline-directed …

Background—Renin–angiotensin aldosterone system (RAAS) inhibitors significantly
improve outcome in heart failure (HF) patients with reduced ejection fraction (HFREF) …

Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …

The incidence of heart failure is primarily flat or declining for a presumably reflecting better
management of cardiovascular diseases, but that of heart failure with preserved ejection …

CKD is common in patients with heart failure, associated with high mortality and morbidity,
which is even higher in people undergoing long-term dialysis. Despite increasing use of …

Background Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin
receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …